CR11221A - Estirpes celulares aviares inmortalizadas - Google Patents

Estirpes celulares aviares inmortalizadas

Info

Publication number
CR11221A
CR11221A CR11221A CR11221A CR11221A CR 11221 A CR11221 A CR 11221A CR 11221 A CR11221 A CR 11221A CR 11221 A CR11221 A CR 11221A CR 11221 A CR11221 A CR 11221A
Authority
CR
Costa Rica
Prior art keywords
immortalized
stones
cells
aircraft cellular
aircraft
Prior art date
Application number
CR11221A
Other languages
English (en)
Inventor
Philipppe Erbs
Marina Kapfer
Nathalie Silvestre
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39767102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11221(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of CR11221A publication Critical patent/CR11221A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a celulas aviares inmortalizadas, y al uso de estas celulas para la produccion de virus. Las celulas segun la invencion son particularmente utiles para la produccion de vectores viricos recombinantes que se pueden usar para la preparacion de composiciones terapeuticas y/o profilacticas para el tratamiento de animales, y mas particularmente seres humanos.
CR11221A 2007-07-03 2010-01-15 Estirpes celulares aviares inmortalizadas CR11221A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07360030 2007-07-03

Publications (1)

Publication Number Publication Date
CR11221A true CR11221A (es) 2010-03-22

Family

ID=39767102

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11221A CR11221A (es) 2007-07-03 2010-01-15 Estirpes celulares aviares inmortalizadas

Country Status (15)

Country Link
US (2) US8361788B2 (es)
EP (1) EP2176398B1 (es)
JP (1) JP5421250B2 (es)
KR (1) KR101528379B1 (es)
CN (1) CN101688182A (es)
AU (1) AU2008270317B2 (es)
BR (1) BRPI0811787B1 (es)
CA (1) CA2691868C (es)
CR (1) CR11221A (es)
ES (1) ES2618490T3 (es)
IL (1) IL203029A (es)
RU (1) RU2475536C2 (es)
TW (1) TWI614342B (es)
WO (1) WO2009004016A1 (es)
ZA (1) ZA201000251B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8357531B2 (en) * 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
KR20120026526A (ko) 2009-05-12 2012-03-19 트랜스진 에스.에이. 불멸화 조류 세포주 및 그의 용도
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
FR2956409A1 (fr) 2010-02-15 2011-08-19 Univ Claude Bernard Lyon Procedes pour optimiser la production virale par l'inactivation ou l'inhibition du gene hipk2 et cellules modifiees pour la production virale
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
JP2014518080A (ja) 2011-06-27 2014-07-28 バルネバ 細胞のスクリーニング方法
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
CA2878800A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
CN104726409B (zh) * 2013-12-19 2017-12-29 普莱柯生物工程股份有限公司 一种永生化的鸭胚肝细胞系的制备方法和应用
RU2695462C2 (ru) 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
DK3226894T3 (da) 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
RU2694318C2 (ru) * 2014-12-04 2019-07-11 Интервет Интернэшнл Б.В. Иммортализованные фибробласты эмбриона цыпленка
EP3256156B1 (en) 2015-02-13 2025-02-12 Transgene Immunotherapeutic vaccine and antibody combination therapy
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
KR102658198B1 (ko) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
CA3061678A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
KR102684237B1 (ko) 2017-06-21 2024-07-11 트랜스진 개인 맞춤형 백신
CA3111273C (en) 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
EP3884039A1 (en) 2018-11-23 2021-09-29 Valneva SE Food products comprising avian stem cells
FR3089789B1 (fr) 2018-12-14 2022-05-27 Univ Claude Bernard Lyon Production de vaccins viraux sur une lignee cellulaire aviaire
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
BR112022017438A2 (pt) 2020-03-12 2022-10-18 Bavarian Nordic As Composições que melhoram a estabilidade do poxvírus
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749021B1 (fr) * 1996-05-23 2001-10-26 Agronomique Inst Nat Rech Lignees de cellules aviaires immortalisees
US5672485A (en) * 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
FR2836924B1 (fr) * 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
PT1649023E (pt) 2003-07-21 2008-11-20 Transgene Sa Polipéptido com actividade de citosina desaminase melhorada
CA2531565C (en) 2003-07-22 2014-02-11 Vivalis Production of poxviruses with adherent or non adherent avian cell lines
EP1528101A1 (en) * 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production

Also Published As

Publication number Publication date
US20100197010A1 (en) 2010-08-05
RU2010102668A (ru) 2011-08-10
KR101528379B1 (ko) 2015-06-16
AU2008270317A1 (en) 2009-01-08
KR20100035650A (ko) 2010-04-05
JP5421250B2 (ja) 2014-02-19
ES2618490T3 (es) 2017-06-21
CN101688182A (zh) 2010-03-31
AU2008270317B2 (en) 2013-12-05
TW200911994A (en) 2009-03-16
CA2691868C (en) 2016-12-20
BRPI0811787A2 (pt) 2014-12-30
US8361788B2 (en) 2013-01-29
RU2475536C2 (ru) 2013-02-20
BRPI0811787B1 (pt) 2018-10-09
US20130244246A1 (en) 2013-09-19
ZA201000251B (en) 2010-09-29
US8809056B2 (en) 2014-08-19
TWI614342B (zh) 2018-02-11
EP2176398B1 (en) 2016-12-28
IL203029A (en) 2013-07-31
EP2176398A1 (en) 2010-04-21
JP2010531654A (ja) 2010-09-30
CA2691868A1 (en) 2009-01-08
WO2009004016A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
CR11221A (es) Estirpes celulares aviares inmortalizadas
CL2021000088A1 (es) Anticuerpos anti-cd27 (divisional de solicitud 779-2019).
UY36966A (es) Derivados de heterociclos bicíclicos fusionados como plaguicidas
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
HN2008000087A (es) Inhibidores de la proteasa ns3 del vhc
CY1119216T1 (el) Φαρμακευτικη συνθεση για εισπνοη
MX2019002606A (es) Formulaciones de (r)-2-amino-3-fenilpropil carbamato.
CR9131A (es) Oligonucleotidos inmunoestimuladores de clase c semiblandos
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
UY33625A (es) Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos
PA8650801A1 (es) Composiciones y formulaciones de ecteinascidina, como la ecteinascidina 743
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
CY1117778T1 (el) Βελτιωμενη ανασυνδυασμενη ανθρωπινη ωοθυλακιοτροπο ορμονη
UY32457A (es) Vacuna del virus del dengue inactivado
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CR20200649A (es) Agosnistas de tlr7
UY33633A (es) ?combinación sinérgica de abamectina y bifentrina, su proceso de preparación y uso, y método utilizando la misma"
UY29189A1 (es) Nonadepsipeptidos acilados ii
CL2018002368A1 (es) Formulaciones de oritavancina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)